Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease

Bruno P. Imbimbo, P. Martelli, W. M. Troetel, F. Lucchelli, U. Lucca, L. J. Thal

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy and safety of eptastigmine in patients with moderate to moderately severe AD. Background: Eptastigmine is a centrally acting cholinesterase inhibitor. Methods: The study was carried out according a multicenter, randomized, double-blinded, placebo-controlled, parallel-group design. Patients received a 24-week treatment with placebo or eptastigmine 15 mg or 20 mg three times daily after a 4-week, stepwise dose escalation. The effects of treatment on cognition, global function, and activities of daily living were evaluated with the Alzheimer's Disease Assessment Cognitive Subscale (ADAS-Cog), the Clinician's Interview-Based Impression of Change Plus (CIBIC-Plus), and the Instrumental Activities of Daily Living scale (IADL), respectively. Results: Thirty-six centers recruited 491 patients: 164 on placebo, 166 on eptastigmine 15 mg three times daily, and 161 on eptastigmine 20 mg three times daily. Percentages of patients completing double-blinded treatment were 87% in the placebo group and 86% in both the eptastigmine-treated groups. At the end of treatment, the intent-to-treat analysis on 463 patients showed a dose-dependent effect of eptastigmine on all efficacy variables, with a statistically significant effect of the 20 mg three times daily dose compared with placebo on the ADAS- Cog, CIBIC-Plus, and IADL. Patients on eptastigmine 15 mg three times daily performed significantly better than placebo-treated patients only on the ADAS-Cog. Eleven patients on placebo (7%), 13 patients on eptastigmine 15 mg three times daily (8%), and 12 patients on eptastigmine 20 mg three times daily (8%) discontinued study treatment because of adverse events. Adverse events were recorded in 49% of patients on placebo compared with 54% on eptastigmine 15 mg three times daily and 48% on eptastigmine 20 mg three times daily. Cholinergic side effects (nausea, vomiting, diarrhea, and abdominal pain) were reported with similar frequency in the eptastigmine- and placebo-treated patients. There was a dose-dependent transient and mild neutropenic effect associated with eptastigmine treatment, and one patient on 20 mg three times daily had an asymptomatic pancytopenia. Conclusions: Eptastigmine produces significant cognitive, clinical, and functional benefits in patients with probable AD. Although the cholinergic tolerability of eptastigmine was found to be favorable, its potential adverse hematologic effects limit its clinical utility.

Original languageEnglish
Pages (from-to)700-708
Number of pages9
JournalNeurology
Volume52
Issue number4
Publication statusPublished - Mar 10 1999

Fingerprint

Alzheimer Disease
Safety
Placebos
Therapeutics
Activities of Daily Living
physostigmine heptyl
Cholinergic Agents
Interviews
Pancytopenia
Cholinesterase Inhibitors
Cognition
Nausea
Abdominal Pain
Vomiting
Diarrhea

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Imbimbo, B. P., Martelli, P., Troetel, W. M., Lucchelli, F., Lucca, U., & Thal, L. J. (1999). Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. Neurology, 52(4), 700-708.

Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. / Imbimbo, Bruno P.; Martelli, P.; Troetel, W. M.; Lucchelli, F.; Lucca, U.; Thal, L. J.

In: Neurology, Vol. 52, No. 4, 10.03.1999, p. 700-708.

Research output: Contribution to journalArticle

Imbimbo, BP, Martelli, P, Troetel, WM, Lucchelli, F, Lucca, U & Thal, LJ 1999, 'Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease', Neurology, vol. 52, no. 4, pp. 700-708.
Imbimbo BP, Martelli P, Troetel WM, Lucchelli F, Lucca U, Thal LJ. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. Neurology. 1999 Mar 10;52(4):700-708.
Imbimbo, Bruno P. ; Martelli, P. ; Troetel, W. M. ; Lucchelli, F. ; Lucca, U. ; Thal, L. J. / Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. In: Neurology. 1999 ; Vol. 52, No. 4. pp. 700-708.
@article{2ff7e5d62caf4c6884085f3cebb6c4e2,
title = "Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease",
abstract = "Objective: To evaluate the efficacy and safety of eptastigmine in patients with moderate to moderately severe AD. Background: Eptastigmine is a centrally acting cholinesterase inhibitor. Methods: The study was carried out according a multicenter, randomized, double-blinded, placebo-controlled, parallel-group design. Patients received a 24-week treatment with placebo or eptastigmine 15 mg or 20 mg three times daily after a 4-week, stepwise dose escalation. The effects of treatment on cognition, global function, and activities of daily living were evaluated with the Alzheimer's Disease Assessment Cognitive Subscale (ADAS-Cog), the Clinician's Interview-Based Impression of Change Plus (CIBIC-Plus), and the Instrumental Activities of Daily Living scale (IADL), respectively. Results: Thirty-six centers recruited 491 patients: 164 on placebo, 166 on eptastigmine 15 mg three times daily, and 161 on eptastigmine 20 mg three times daily. Percentages of patients completing double-blinded treatment were 87{\%} in the placebo group and 86{\%} in both the eptastigmine-treated groups. At the end of treatment, the intent-to-treat analysis on 463 patients showed a dose-dependent effect of eptastigmine on all efficacy variables, with a statistically significant effect of the 20 mg three times daily dose compared with placebo on the ADAS- Cog, CIBIC-Plus, and IADL. Patients on eptastigmine 15 mg three times daily performed significantly better than placebo-treated patients only on the ADAS-Cog. Eleven patients on placebo (7{\%}), 13 patients on eptastigmine 15 mg three times daily (8{\%}), and 12 patients on eptastigmine 20 mg three times daily (8{\%}) discontinued study treatment because of adverse events. Adverse events were recorded in 49{\%} of patients on placebo compared with 54{\%} on eptastigmine 15 mg three times daily and 48{\%} on eptastigmine 20 mg three times daily. Cholinergic side effects (nausea, vomiting, diarrhea, and abdominal pain) were reported with similar frequency in the eptastigmine- and placebo-treated patients. There was a dose-dependent transient and mild neutropenic effect associated with eptastigmine treatment, and one patient on 20 mg three times daily had an asymptomatic pancytopenia. Conclusions: Eptastigmine produces significant cognitive, clinical, and functional benefits in patients with probable AD. Although the cholinergic tolerability of eptastigmine was found to be favorable, its potential adverse hematologic effects limit its clinical utility.",
author = "Imbimbo, {Bruno P.} and P. Martelli and Troetel, {W. M.} and F. Lucchelli and U. Lucca and Thal, {L. J.}",
year = "1999",
month = "3",
day = "10",
language = "English",
volume = "52",
pages = "700--708",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease

AU - Imbimbo, Bruno P.

AU - Martelli, P.

AU - Troetel, W. M.

AU - Lucchelli, F.

AU - Lucca, U.

AU - Thal, L. J.

PY - 1999/3/10

Y1 - 1999/3/10

N2 - Objective: To evaluate the efficacy and safety of eptastigmine in patients with moderate to moderately severe AD. Background: Eptastigmine is a centrally acting cholinesterase inhibitor. Methods: The study was carried out according a multicenter, randomized, double-blinded, placebo-controlled, parallel-group design. Patients received a 24-week treatment with placebo or eptastigmine 15 mg or 20 mg three times daily after a 4-week, stepwise dose escalation. The effects of treatment on cognition, global function, and activities of daily living were evaluated with the Alzheimer's Disease Assessment Cognitive Subscale (ADAS-Cog), the Clinician's Interview-Based Impression of Change Plus (CIBIC-Plus), and the Instrumental Activities of Daily Living scale (IADL), respectively. Results: Thirty-six centers recruited 491 patients: 164 on placebo, 166 on eptastigmine 15 mg three times daily, and 161 on eptastigmine 20 mg three times daily. Percentages of patients completing double-blinded treatment were 87% in the placebo group and 86% in both the eptastigmine-treated groups. At the end of treatment, the intent-to-treat analysis on 463 patients showed a dose-dependent effect of eptastigmine on all efficacy variables, with a statistically significant effect of the 20 mg three times daily dose compared with placebo on the ADAS- Cog, CIBIC-Plus, and IADL. Patients on eptastigmine 15 mg three times daily performed significantly better than placebo-treated patients only on the ADAS-Cog. Eleven patients on placebo (7%), 13 patients on eptastigmine 15 mg three times daily (8%), and 12 patients on eptastigmine 20 mg three times daily (8%) discontinued study treatment because of adverse events. Adverse events were recorded in 49% of patients on placebo compared with 54% on eptastigmine 15 mg three times daily and 48% on eptastigmine 20 mg three times daily. Cholinergic side effects (nausea, vomiting, diarrhea, and abdominal pain) were reported with similar frequency in the eptastigmine- and placebo-treated patients. There was a dose-dependent transient and mild neutropenic effect associated with eptastigmine treatment, and one patient on 20 mg three times daily had an asymptomatic pancytopenia. Conclusions: Eptastigmine produces significant cognitive, clinical, and functional benefits in patients with probable AD. Although the cholinergic tolerability of eptastigmine was found to be favorable, its potential adverse hematologic effects limit its clinical utility.

AB - Objective: To evaluate the efficacy and safety of eptastigmine in patients with moderate to moderately severe AD. Background: Eptastigmine is a centrally acting cholinesterase inhibitor. Methods: The study was carried out according a multicenter, randomized, double-blinded, placebo-controlled, parallel-group design. Patients received a 24-week treatment with placebo or eptastigmine 15 mg or 20 mg three times daily after a 4-week, stepwise dose escalation. The effects of treatment on cognition, global function, and activities of daily living were evaluated with the Alzheimer's Disease Assessment Cognitive Subscale (ADAS-Cog), the Clinician's Interview-Based Impression of Change Plus (CIBIC-Plus), and the Instrumental Activities of Daily Living scale (IADL), respectively. Results: Thirty-six centers recruited 491 patients: 164 on placebo, 166 on eptastigmine 15 mg three times daily, and 161 on eptastigmine 20 mg three times daily. Percentages of patients completing double-blinded treatment were 87% in the placebo group and 86% in both the eptastigmine-treated groups. At the end of treatment, the intent-to-treat analysis on 463 patients showed a dose-dependent effect of eptastigmine on all efficacy variables, with a statistically significant effect of the 20 mg three times daily dose compared with placebo on the ADAS- Cog, CIBIC-Plus, and IADL. Patients on eptastigmine 15 mg three times daily performed significantly better than placebo-treated patients only on the ADAS-Cog. Eleven patients on placebo (7%), 13 patients on eptastigmine 15 mg three times daily (8%), and 12 patients on eptastigmine 20 mg three times daily (8%) discontinued study treatment because of adverse events. Adverse events were recorded in 49% of patients on placebo compared with 54% on eptastigmine 15 mg three times daily and 48% on eptastigmine 20 mg three times daily. Cholinergic side effects (nausea, vomiting, diarrhea, and abdominal pain) were reported with similar frequency in the eptastigmine- and placebo-treated patients. There was a dose-dependent transient and mild neutropenic effect associated with eptastigmine treatment, and one patient on 20 mg three times daily had an asymptomatic pancytopenia. Conclusions: Eptastigmine produces significant cognitive, clinical, and functional benefits in patients with probable AD. Although the cholinergic tolerability of eptastigmine was found to be favorable, its potential adverse hematologic effects limit its clinical utility.

UR - http://www.scopus.com/inward/record.url?scp=0033541027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033541027&partnerID=8YFLogxK

M3 - Article

C2 - 10078713

AN - SCOPUS:0033541027

VL - 52

SP - 700

EP - 708

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 4

ER -